Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AgeX Therapeutics Inc.

Division of BioTime Inc.

Latest From AgeX Therapeutics Inc.

Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m

Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.

Financing Business Strategies

Venture Funding Deals: Gene Editing Attracts Big Investors, Roivant Sets Financing Record

In the largest private biopharma round to date, Roivant raises $1.1bn to fund new subsidiaries. The next highest round in August was for gene-editing-focused Homology Medicines.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • BioTime Inc.
  • Senior Management
  • Michael D West, PhD, CEO
    Russell Skibsted, Interim CFO
    Hal Sternberg, PhD, VP, Rsch.
  • Contact Info
  • AgeX Therapeutics Inc.
    Phone: (510) 871-4190
    1010 Atlantic Ave., Ste. 102
    Alameda, CA 94501